cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Eiger Biopharmaceuticals Inc
2 own
10 watching
Current Price
$1.9
$0.25
(15.15%)
logo-eigr
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
83.69M
52-Week High
52-Week High
10.0213
52-Week Low
52-Week Low
0.96
Average Volume
Average Volume
1.5M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization83.69M
icon52-Week High10.0213
icon52-Week Low0.96
iconAverage Volume1.5M
iconDividend Yield--
iconP/E Ratio--
What does the Eiger Biopharmaceuticals Inc do?
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company s product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Read More
How much money does Eiger Biopharmaceuticals Inc make?
News & Events about Eiger Biopharmaceuticals Inc.
PR Newswire
23days ago
FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm PR Newswire LOS...
Globe Newswire
23days ago
LOS ANGELES, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. ...
Business Wire
23days ago
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Eiger BioPharmaceuticals, Inc. (Eiger or the Company) (NASDAQ: EIGR) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise...
Business Wire
25days ago
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Eiger Biopharmaceuticals, Inc. (Eiger or the Company) (NASDAQ: EIGR) in the United States District Court of Northern California on behalf of...
PR Newswire
26days ago
EIGR SHAREHOLDER ALERT: Jakubowitz Law Reminds Eiger Shareholders of a Lead Plaintiff Deadline of January 9, 2023 EIGR SHAREHOLDER ALERT: Jakubowitz Law Reminds Eiger Shareholders of a Lead Plaintiff Deadline of January 9, 2023 PR Newswire NEW YORK, Jan. 6, 2023 NEW YORK, Jan. 6, 2023 /PRNewswire...
Frequently Asked Questions
Frequently Asked Questions
What is Eiger Biopharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Eiger Biopharmaceuticals Inc shares?
plus_minus_icon
How can I buy Eiger Biopharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Eiger Biopharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Eiger Biopharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Eiger Biopharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Eiger Biopharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Eiger Biopharmaceuticals Inc?
plus_minus_icon
What percentage is Eiger Biopharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Eiger Biopharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.9
$0.25
(15.15%)
logo-eigr
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00